Form 4 HUMANIGEN, INC For: Oct 18 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC Oct 20, 2023 06:51PM
Form 4 HUMANIGEN, INC For: May 18 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC May 20, 2022 05:58PM
Form 4 HUMANIGEN, INC For: Mar 11 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC Mar 15, 2022 06:24PM
Form 4 HUMANIGEN, INC For: Mar 08 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC Mar 10, 2022 07:25PM
Form 4 HUMANIGEN, INC For: Mar 02 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC Mar 4, 2022 06:43PM


Aug 13, 2021 09:28PM Form 4 HUMANIGEN, INC For: Aug 11 Filed by: BLACK HORSE CAPITAL LP
Jul 30, 2021 09:02PM Form 4 HUMANIGEN, INC For: Jul 28 Filed by: BLACK HORSE CAPITAL LP
Jul 23, 2021 08:32PM Form 4 HUMANIGEN, INC For: Jul 21 Filed by: BLACK HORSE CAPITAL LP
Jul 16, 2021 08:28PM Form 4 HUMANIGEN, INC For: Jul 14 Filed by: BLACK HORSE CAPITAL LP
Jul 9, 2021 09:02PM Form 4 HUMANIGEN, INC For: Jul 08 Filed by: BLACK HORSE CAPITAL LP
Jul 2, 2021 05:44PM Form 4 HUMANIGEN, INC For: Jun 30 Filed by: BLACK HORSE CAPITAL LP
Jun 25, 2021 09:03PM Form 4 HUMANIGEN, INC For: Jun 23 Filed by: BLACK HORSE CAPITAL LP
Jun 21, 2021 08:57PM Form 4 HUMANIGEN, INC For: Jun 16 Filed by: BLACK HORSE CAPITAL LP
Jun 9, 2021 04:45PM Form 4 HUMANIGEN, INC For: Jun 07 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC
Jun 4, 2021 06:08PM Form 4 HUMANIGEN, INC For: Jun 02 Filed by: BLACK HORSE CAPITAL MANAGEMENT LLC
Feb 8, 2021 07:16AM Humanigen Inc. (HGEN) Reports Election of Dr. Dale Chappell to Board
Feb 8, 2021 07:00AM Humanigen Elects Dr. Dale Chappell to Board of Directors
Jul 7, 2020 07:00AM Humanigen Appoints Senior Executives to Management Team
Dec 11, 2019 08:00AM Humanigen's GM-CSF Knockout Data Presented at the 2019 Annual Meeting of American Society of Hematology Receives Award
Oct 15, 2019 08:00AM Humanigen Announces Exploration of Potential Rights Offering
Jul 22, 2019 08:00AM Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich
Jul 2, 2019 08:30AM Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
May 31, 2019 08:32AM Kite (GILD) and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta With lenzilumab in R/R DLBCL
May 31, 2019 08:31AM Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
May 16, 2019 05:00PM Publication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced Neurotoxicity
Apr 1, 2019 08:04AM Humanigen Inc. (HGEN) Highlights Prelim. Results from Ifabotuzumab Phase I Study at AACR Meetings
Apr 1, 2019 08:00AM Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Mar 21, 2019 05:00PM Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy
Feb 25, 2019 08:00AM Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
Feb 15, 2019 08:00AM Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)
Jan 3, 2019 04:08PM Humanigen Inc. (HGEN) Reports Publication of New Research Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer & Other Solid Tumor Therapy
Jan 3, 2019 04:05PM Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’
Dec 4, 2018 07:30AM Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
Nov 30, 2018 07:30AM Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition
Nov 2, 2018 08:00AM Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)
Aug 20, 2018 08:00AM Humanigen Announces Positive Topline Study Results
May 2, 2018 04:10PM Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy
Apr 30, 2018 07:00AM Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
Apr 16, 2018 07:00AM Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
Mar 15, 2018 07:00AM Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
Mar 1, 2018 04:50PM Form SC 13D/A HUMANIGEN, INC Filed by: BLACK HORSE CAPITAL LP
Feb 27, 2018 04:05PM Humanigen Completes Exchange of Loan Obligations for Equity
Jan 26, 2018 05:16PM Form SC 13D/A HUMANIGEN, INC Filed by: BLACK HORSE CAPITAL LP
Dec 21, 2017 04:45PM Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity